Recent update on the PPAR alpha-null mouse

被引:88
作者
Gonzalez, FJ
机构
[1] Laboratory of Metabolism, Building 37, National Cancer Institute, Bethesda
关键词
peroxisome proliferation; PPAR alpha; non-genotoxic carcinogens; inflammatory response; gene expression;
D O I
10.1016/S0300-9084(97)81506-4
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 [生物化学与分子生物学]; 081704 [应用化学];
摘要
Short-term treatment of rats and mice with peroxisome proliferators (PP) results in an increase in liver peroxisome number, marked hepatomegaly and induction of several genes encoding peroxisomal and other microsomal and mitochondrial enzymes involved in fatty acid metabolism. Chronic treatment of rodents with PP results in hepatocellular carcinoma. Species differences in PP responses have been found. For example, PP such as clofibrate and gemfibrozil, are highly effective lipid and cholesterol lowering drugs in humans but do not cause peroxisome proliferation and there is no evidence for increased liver cancers in patients receiving these drugs. A receptor, designated PP-activated receptor alpha (PPAR alpha) is capable of trans activating reporter genes containing a PP response (PPRE), but requires the presence of both PP, 9-cis retinoic acid and another receptor called RXR alpha. However, PP may not directly bind to PPAR alpha but probably indirectly disturb cellular metabolism to liberate an endogenous ligand. Subsequent to the first identification of a PPAR alpha, other members of this receptor family were found and designated PPAR alpha, PPAR beta (also called NUC1 and PPAR delta) and PPAR gamma. The alpha form is most abundant in liver and kidney, sites of peroxisome proliferation while the other two receptors are not significantly expressed in these tissues. On the basis of tissue-specific localization and spectrum of target gene activation, the physiological function of PPAR alpha and PPAR gamma appear to be related to fatty acid metabolism and regulation of adipogenesis, respectively. To gain insight into the function of PPAR alpha and its role in the peroxisome proliferator response and hepatocellular carcinogenesis, gene targeting was used to develop a PPAR alpha-deficient mouse. These animals are resistant to the pleiotropic effects of PP and no induction of any known target gene has been found. Recent studies on the phenotypes of these mice have led to an understanding of the mechanism of action of PP. They have also provided a useful model to establish the physiological role of PPAR alpha in fatty acid homeostasis and inflammation.
引用
收藏
页码:139 / 144
页数:6
相关论文
共 35 条
[1]
Dehydroepiandrosterone (DHEA): A fountain of youth? [J].
Baulieu, EE .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1996, 81 (09) :3147-3151
[2]
SUPPRESSION OF LIVER-CELL APOPTOSIS IN-VITRO BY THE NONGENOTOXIC HEPATOCARCINOGEN AND PEROXISOME PROLIFERATOR NAFENOPIN [J].
BAYLY, AC ;
ROBERTS, RA ;
DIVE, C .
JOURNAL OF CELL BIOLOGY, 1994, 125 (01) :197-203
[3]
Differential expression of peroxisome proliferator-activated receptors (PPARs): Tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat [J].
Braissant, O ;
Foufelle, F ;
Scotto, C ;
Dauca, M ;
Wahli, W .
ENDOCRINOLOGY, 1996, 137 (01) :354-366
[4]
TRANSFORMATION OF MAMMALIAN-CELLS BY OVEREXPRESSING H2O2-GENERATING PEROXISOMAL FATTY ACYL-COA OXIDASE [J].
CHU, S ;
HUANG, Q ;
ALVARES, K ;
YELDANDI, AV ;
RAO, MS ;
REDDY, JK .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (15) :7080-7084
[5]
Dehydroepiandrosterone and body fat [J].
Clore, JN .
OBESITY RESEARCH, 1995, 3 :S613-S616
[6]
The PPAR alpha-leukotriene B-4 pathway to inflammation control [J].
Devchand, PR ;
Keller, H ;
Peters, JM ;
Vazquez, M ;
Gonzalez, FJ ;
Wahli, W .
NATURE, 1996, 384 (6604) :39-43
[7]
FATTY-ACID ACTIVATION OF THE PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR, A MEMBER OF THE NUCLEAR RECEPTOR GENE SUPERFAMILY [J].
GEARING, KL ;
GOTTLICHER, M ;
WIDMARK, E ;
BANNER, CD ;
TOLLET, P ;
STROMSTEDT, M ;
RAFTER, JJ ;
BERGE, RK ;
GUSTAFSSON, JA .
JOURNAL OF NUTRITION, 1994, 124 (08) :S1284-S1288
[8]
GORDON GB, 1991, CANCER RES, V51, P1366
[9]
FATTY-ACIDS ACTIVATE A CHIMERA OF THE CLOFIBRIC ACID-ACTIVATED RECEPTOR AND THE GLUCOCORTICOID RECEPTOR [J].
GOTTLICHER, M ;
WIDMARK, E ;
LI, Q ;
GUSTAFSSON, JA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (10) :4653-4657
[10]
PPAR: A mediator of peroxisome proliferator action [J].
Green, S .
MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS, 1995, 333 (1-2) :101-109